UK Markets open in 7 hrs 43 mins
  • NIKKEI 225

    27,782.42
    +200.76 (+0.73%)
     
  • HANG SENG

    26,315.32
    +841.44 (+3.30%)
     
  • CRUDE OIL

    73.35
    -0.27 (-0.37%)
     
  • GOLD FUTURES

    1,834.00
    -1.80 (-0.10%)
     
  • DOW

    35,084.53
    +153.60 (+0.44%)
     
  • BTC-GBP

    28,583.11
    -62.13 (-0.22%)
     
  • CMC Crypto 200

    935.12
    +4.76 (+0.51%)
     
  • Nasdaq

    14,778.26
    +15.68 (+0.11%)
     
  • ^FTAS

    4,054.12
    +30.04 (+0.75%)
     

Dry Eye Disease Clinical Landscape Report 2021: Novartis Leads Industry Sponsors with the Highest Overall Number of Clinical Trials, Followed by AbbVie

·3-min read

Dublin, July 08, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Dry Eye Disease" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Systemic Lupus Erythematosus (SLE) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

  • The publisher estimates that in 2020, there were 1.52 billion prevalent cases of dry eye worldwide, and forecasts that number to increase to 1.72 billion prevalent cases by 2029.

  • The approved drugs in the dry eye space focus on a wide variety of targets. The majority of approved drugs are administered via the topical route, with one product available as an intraocular/subretinal/subconjunctival formulation.

  • The majority of industry-sponsored drugs in active clinical development for dry eye are in Phase II, with only one drug in the NDA/BLA phase.

  • Therapies in development for dry eye focus on a wide variety of targets. The majority of pipeline drugs are administered via the topical route, with the remainder being intranasal, oral, and intraocular/subretinal/subconjunctival formulations.

  • High-impact upcoming events for drugs in the dry eye space comprise topline Phase II trial results for NRO-1, ECF843, and OTXCSI; topline Phase IIb trial results for AR-15512; topline Phase III trial results for MIM-D3 and CyclASol; and an expected PDUFA date for OC-01 Nasal Spray.

  • The overall likelihood of approval of a Phase I ophthalmology-other asset is 22.8%, and the average probability a drug advances from Phase III is 55%. Drugs, on average, take 8.6 years from Phase I to approval, compared to 8.9 years in the overall ophthalmology space.

  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for dry eye have been in the late phases of development, with 56% of trials in Phase III-IV, and only 44% in Phase I-II.

  • The US has a substantial lead in the number of dry eye clinical trials globally. France leads the major European markets, while Japan has the top spot in Asia.

  • Clinical trial activity in the dry eye space is dominated by completed trials. Novartis has the highest number of completed clinical trials for dry eye, with 87 trials.

  • Novartis leads industry sponsors with the highest overall number of clinical trials for dry eye, followed by AbbVie.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Definition

  • Patient segmentation

  • Symptoms

  • Risk factors

  • Diagnosis

TREATMENT

  • Ocular lubricants

  • Prescription drugs

  • Eyelid hygiene

  • Surgical treatment

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • NovaTears for Dry Eye (April 13, 2021)

  • RGN-259 for Dry Eye (March 18, 2021)

  • Visomitin for Dry Eye (February 22, 2021)

  • Reproxalap for Dry Eye (January 7, 2021)

  • NovaTears for Dry Eye (December 22, 2020)

  • PL-9643 for Dry Eye (December 15, 2020)

  • Voclosporin Ophthalmic Solution (VOS) for Dry Eye (November 2, 2020)

  • OC-01 Nasal Spray for Dry Eye (May 11, 2020)

  • EYSUVIS for Dry Eye (March 9, 2020)

  • Reproxalap for Dry Eye (December 3, 2019)

  • OC-01 Nasal Spray for Dry Eye (October 4, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Oyster Point Pharma Submits NDA For OC-01 Nasal Spray

  • FDA Approves Eysuvis For Dry Eye Disease

  • EMA Unconvinced By Xiidra Dry Eye Data

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • IACTA Licenses Dry Eye, Conjunctivitis Candidates To Zhaoke

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status

  • Sponsors by phase

  • Recent events

BIBLIOGRAPHY

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/lzswh1

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting